Neutropenia News and Research

RSS

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.

RYBREVANT Receives EC Nod for Advanced Lung Cancer Treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II extension of indication for RYBREVANT®▼ (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (ex19del) or Exon 21 L858R substitution (L858R) mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).

30 Aug 2024

Scientists Engineer the First CRISPR-Based Drug Candidate to Directly Target E. Coli

Many people have experienced infections from E. coli, which are primarily seen as inconvenient and unpleasant.

10 May 2023

Novel adoptive T cell receptor therapy shows promising results for patients with solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

30 Jan 2023

Study reveals genetic architecture of COVID-19 risk factors and disease complications

According to a recent study of information from the Veterans Affairs Million Veteran Program, there are genetic correlations between COVID-19 severity and specific medical disorders that are established risk factors for severe COVID-19.

3 May 2022

Study identifies molecular mechanism by which HSPCs recover after chemotherapy-induced injury

Chemotherapy has a damaging effect on hematopoietic stem and progenitor cells (HSPCs) in bone marrow. However, once chemotherapy ends, HSPCs regenerate, a process that has remained unknown--until now.

From Osaka University 8 Mar 2021

Subcutaneous injection of teclistamab drug shows promise in treating aggressive multiple myeloma

A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma, according to findings from a multi-institutional phase I study being presented by Alfred L. Garfall, MD, an assistant professor of Medicine in the division of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania, at the annual American Society of Hematology & Exposition Meeting on Dec. 5 (abstract #180).

7 Dec 2020

Research projects receive BTCA awards to develop new drugs

Five research projects with exceptional promise to deliver new life-changing and health-altering therapies have received the inaugural Blavatnik Therapeutics Challenge Awards (BTCA) at Harvard Medical School.

From Harvard Medical School 30 Oct 2020

Study pinpoints specific protein involved in the mass production of antibodies

A team of researchers has discovered how a specific protein called JAGN1 plays a crucial role in the production of antibodies.

17 Sep 2020

Combination regimen improves overall survival in acute myeloid leukemia patients

A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.

13 Aug 2020

Researchers develop new molecular workflow to study single-cell genomics of diseases

Although advances in genetics and genomics reveal numerous disease-associated gene mutations, physicians and researchers still wrestle with the tricky challenge of linking those mutations to actual disease-causing processes.

23 Apr 2020